- Home
- BQ vs NRSN Comparison
BQ vs NRSN Comparison
Compare BQ & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BQ | NRSN |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.6M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BQ | NRSN |
|---|---|---|
| Price | $0.72 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $97.33 |
| AVG Volume (30 Days) | ★ 33.8K | 17.6K |
| Earning Date | 07-13-2026 | 09-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.25 |
| 52 Week High | $72.74 | $7.50 |
Technical Indicators
Market Signals| Indicator | BQ | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 33.04 | 44.05 |
| Support Level | $0.70 | $0.63 |
| Resistance Level | $0.89 | $7.50 |
| Average True Range (ATR) | 0.04 | 0.62 |
| MACD | -0.01 | -0.41 |
| Stochastic Oscillator | 0.12 | 1.61 |
Price Performance
Historical ComparisonAbout BQ Boqii Holding Limited representing
Boqii Holding Ltd is a pet-focused platform in China. It offer a truly one-stop destination that pet parents in China may go to get everything it need for their pets and share their passion for pet parenting. It operate a pet-focused online retail business in China's pet market in terms of GMV. The company operates in single segment. This segment is engaged in pet products sales and online marketing and information services and other. All the company's revenues is derived from The PRC.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.